← Back to Search

Prebiotic Fiber

Inulin for ICU Infections

Phase 2

Waitlist Available

Led By Daniel E Freedberg, MD, MS

Research Sponsored by Columbia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥ 18 years old at the time of hospitalization

Received broad-spectrum antibiotics within the last 24 hours or ordered and pending administration

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through day 3 and through day 7

Awards & highlights

Study Summary

This trial will test whether inulin is safe and may help to prevent antibiotic resistant infections in the ICU.

Who is the study for?

This trial is for adults over 18 in the ICU with sepsis who've recently started antibiotics. It's not for those allergic to inulin, with very low sodium levels, weakened immune systems from certain treatments or conditions, recent gut surgery, strict 'do not resuscitate' orders, or unable to consent without a legal rep.Check my eligibility

What is being tested?

The study tests if inulin (a prebiotic fiber) can prevent antibiotic-resistant infections by improving gut health in critically ill patients. Participants will either receive an inulin oral suspension or a placebo while being monitored for safety and effectiveness against resistant pathogens.See study design

What are the potential side effects?

While specific side effects of inulin are not detailed here, it may include digestive discomfort like bloating or gas. The trial aims to assess its tolerability and safety among ICU patients.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have taken broad-spectrum antibiotics in the last 24 hours.

Select...

I am currently admitted in a medical ICU that is part of the study.

Select...

I have sepsis with a significant increase in my SOFA score.

Select...

I can start the study within 4 hours of being admitted to the ICU.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through day 3 and through day 7

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through day 3 and through day 7

This trial's timeline: 3 weeks for screening, Varies for treatment, and through day 3 and through day 7 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

MDR infections

MDRO colonization status

Within-individual change in SCFA producer level

Secondary outcome measures

ICU length of stay (LOS)

Multi-omic approach to changes related to inulin

Nutritional intake

Trial Design

3Treatment groups

Experimental Treatment

Placebo Group

Group I: Inulin 32 g/dayExperimental Treatment2 Interventions

Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (16g twice daily) for a minimum of 7 days.

Group II: Inulin 16 g/dayExperimental Treatment2 Interventions

Critically ill adults who are receiving broad-spectrum antibiotics will also receive inulin oral suspension (8g twice daily) for a minimum of 7 days.

Group III: PlaceboPlacebo Group2 Interventions

Critically ill adults who are receiving broad-spectrum antibiotics will also receive placebo oral suspension for a minimum of 7 days.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Broad-spectrum antibiotics

2014

N/A

~2480

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor

1,439 Previous Clinical Trials

2,448,729 Total Patients Enrolled

Daniel E Freedberg, MD, MSPrincipal InvestigatorColumbia University

1 Previous Clinical Trials

7 Total Patients Enrolled

Media Library

Inulin (Prebiotic Fiber) Clinical Trial Eligibility Overview. Trial Name: NCT03865706 — Phase 2

Antibiotic Resistance Research Study Groups: Placebo, Inulin 32 g/day, Inulin 16 g/day

Antibiotic Resistance Clinical Trial 2023: Inulin Highlights & Side Effects. Trial Name: NCT03865706 — Phase 2

Inulin (Prebiotic Fiber) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03865706 — Phase 2

~16 spots leftby Jun 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.